Fresenius Medical Care
FMS
#1846
Rank
$11.37 B
Marketcap
$21.92
Share price
-1.37%
Change (1 day)
-8.65%
Change (1 year)

P/E ratio for Fresenius Medical Care (FMS)

P/E ratio as of November 2026 (TTM): 12.9

According to Fresenius Medical Care's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.8725. At the end of 2022 the company had a P/E ratio of 13.6.

P/E ratio history for Fresenius Medical Care from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202213.6-19.05%
202116.9-7.35%
202018.29.25%
201916.794.41%
20188.57-60.75%
201721.86.84%
201620.4-17.46%
201524.814.97%
201421.58.98%
201319.89.37%
201218.1-2.88%
201118.66.84%
201017.40.04%
200917.42.44%
200817.0-23.07%
200722.1-11.87%
200625.126.93%
200519.7-4.86%
200420.7-2.96%
200321.465.9%
200212.9-40.88%
200121.8

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Amgen
AMGN
26.9 109.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
-18.7-245.12%๐Ÿ‡บ๐Ÿ‡ธ USA
DaVita
DVA
13.2 2.70%๐Ÿ‡บ๐Ÿ‡ธ USA
IDEXX Laboratories
IDXX
47.1 265.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Quest Diagnostics
DGX
25.4 97.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Teleflex
TFX
-6.72-152.17%๐Ÿ‡บ๐Ÿ‡ธ USA
LabCorp
LH
30.3 135.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Rockwell Medical
RMTI
-5.28-141.05%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.